| PBHPrestige Consumer Healthcare Inc. |
US$ 1,1 bi |
17,5% |
2026 |
| PRHIPresurance Holdings, Inc. |
US$ 43,3 mi |
-42,6% |
2025 |
| PRIAFPrime Impact Acquisition I |
n/d |
n/d |
2022 |
| PRMEPrime Medicine, Inc. |
US$ 4,6 mi |
-4.342,4% |
2025 |
| PMECPrimech Holdings Ltd |
US$ 74,3 mi |
-2,6% |
2025 |
| PRIPrimerica, Inc. |
US$ 3,3 bi |
22,7% |
2025 |
| FRSTPrimis Financial Corp. |
n/d |
n/d |
2025 |
| PRMBPrimo Brands Corp |
US$ 6,7 bi |
0,9% |
2025 |
| PRIMPrimoris Services Corp |
US$ 7,6 bi |
3,6% |
2025 |
| BPRNPrinceton Bancorp, Inc. |
n/d |
n/d |
2025 |
| PDSKXPrincipal Real Asset Fund |
n/d |
n/d |
n/d |
| PGZPrincipal Real Estate Income Fund |
n/d |
n/d |
n/d |
| PRIF-PDPriority Income Fund, Inc. |
n/d |
n/d |
n/d |
| PRTHPriority Technology Holdings, Inc. |
US$ 953 mi |
5,8% |
2025 |
| PBAMPrivate Bancorp of America, Inc. |
n/d |
n/d |
n/d |
| PRVAPrivia Health Group, Inc. |
US$ 2,1 bi |
1,1% |
2025 |
| PCAPProCap Acquisition Corp |
n/d |
n/d |
2025 |
| BRRProCap Financial, Inc. |
n/d |
n/d |
n/d |
| ACDCProFrac Holding Corp. |
US$ 1,9 bi |
-19,0% |
2025 |
| PMNProMIS Neurosciences Inc. |
n/d |
n/d |
2025 |
| PUMPProPetro Holding Corp. |
US$ 1,3 bi |
0,1% |
2025 |
| PRPHProPhase Labs, Inc. |
US$ 4,3 mi |
-339,3% |
2025 |
| PRQRProQR Therapeutics N.V. |
€ 15,9 mi |
-265,2% |
2025 |
| AGQProShares Trust II |
n/d |
n/d |
2025 |
| PCSAProcessa Pharmaceuticals, Inc. |
n/d |
n/d |
2025 |
| PAACProem Acquisition Corp. I |
n/d |
n/d |
n/d |
| IPDNProfessional Diversity Network, Inc. |
US$ 6,5 mi |
-98,5% |
2025 |
| PALProficient Auto Logistics, Inc |
n/d |
n/d |
2025 |
| PROFProfound Medical Corp. |
US$ 16,1 mi |
-264,4% |
2025 |
| PFSAProfusa, Inc. |
n/d |
n/d |
2025 |
| PGNYProgyny, Inc. |
US$ 1,3 bi |
4,5% |
2025 |
| PLDPrologis, Inc. |
US$ 8,8 bi |
37,9% |
2025 |
| PRLGPrologium Holding Inc. |
n/d |
n/d |
n/d |
| PPCBPropanc Biopharma, Inc. |
n/d |
n/d |
2026 |
| PTIXProtagenic Therapeutics, Inc. |
US$ 0 |
n/d |
2026 |
| PTGXProtagonist Therapeutics, Inc |
US$ 46 mi |
-282,8% |
2025 |
| PLXProtalix BioTherapeutics, Inc. |
US$ 52,7 mi |
-12,5% |
2025 |
| TARAProtara Therapeutics, Inc. |
n/d |
n/d |
2025 |
| PSKRFProtector Forsikring |
n/d |
n/d |
n/d |
| PRLBProto Labs Inc |
US$ 533,1 mi |
4,0% |
2025 |
| PKTXProtoKinetix, Inc. |
n/d |
n/d |
2025 |
| PRYMFPrysmian S.p.A. |
n/d |
n/d |
n/d |
| PUBMPubMatic, Inc. |
US$ 282,9 mi |
-5,1% |
2025 |
| PPHCPublic Policy Holding Company, Inc. |
US$ 186,5 mi |
-20,9% |
2025 |
| PSAPublic Storage |
US$ 4,8 bi |
37,0% |
2025 |
| PULMPulmatrix, Inc. |
n/d |
n/d |
2025 |
| LUNGPulmonx Corp |
US$ 90,5 mi |
-59,7% |
2025 |
| PLSMPulsenmore Ltd. |
US$ 12,5 mi |
-39,6% |
2025 |
| PCTPureCycle Technologies, Inc. |
US$ 8,4 mi |
-2.185,1% |
2025 |
| PRTCYPureTech Health plc |
US$ 4,8 mi |
1.108,3% |
2024 |